GET THE APP

A randomized double-blind placebo-controlled Phase 2A clinical trial of NA-831 in patients with mild cognitive impairment
..

Neurological Disorders

ISSN: 2329-6895

Open Access

A randomized double-blind placebo-controlled Phase 2A clinical trial of NA-831 in patients with mild cognitive impairment


25th World Congress on Neurology and Neurodisorders

July 16-17, 2018 Melbourne, Australia

Brian H Tran and Lloyd L Tran

NeuroActiva Inc., USA

Posters & Accepted Abstracts: J Neurol Disord

Abstract :

Statement of the Problem: Mild Cognitive Impairment (MCI) is defined as the symptomatic pre-dementia stage on the continuum of cognitive decline. Currently, no medications have proven effective for MCI. Preclinical experiments indicate that NA-831 is an endogenous small molecule that exhibits neuroprotection, neurogenesis and cognitive protective properties across a range of disease models. NA-831 has been shown to be safe and well tolerated in healthy volunteers. Methods: A randomized Phase 2A clinical trial of NA-831 was performed in Alzheimer patients with mild cognitive impairment of vascular origin. Inclusion criteria: (1) Male or female, at 55-80 years of age at screening, (2) Mini-Mental State Exam (MMSE) score â?¥20 (primary school) or â?¥24 (high school or above) (3) Center for Epidemiological Studies-Depression (CES-D) score <27. A total of 56 patients were randomly assigned to NA-831 at a daily dosage of 10 mg or matched placebo (1:1) for 24 weeks. Results: The effects of NA-831 on Alzheimer patients with mild cognitive impairment were measured as statistically significant reductions in scores on the BCSR and ADAS-cog scales. Based on the BCRS, the effects of NA-831 were apparent after 8 weeks of treatment (p=0.001), with the significant improvement in the following areas: Fatigue, anxiety, irritability, affective lability, disturbance to waking, daytime drowsiness, headache and nocturnal sleep. NA-831 showed significant improvement with the ADAS-cog score changed 3.21 points (NA-831 change â??4.47 vs. placebo â??1.26; P=0.001; ITT). CIBIC-Plus showed (23 [82.1%] vs. 5 [17.9%]) patients improved; P=0.01; ITT). NA-831 was well-tolerated at high dosage up to 50 mg per day. No adverse effects were reported. Conclusion: Over the 6-month treatment period, NA-831 was effective for improving cognitive and global functioning in patients with mild cognitive impairment. As an endogenous compound, NA-831 is well-tolerated and has excellent safety profile.

Google scholar citation report
Citations: 912

Neurological Disorders received 912 citations as per google scholar report

Neurological Disorders peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward